{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:26:27Z","timestamp":1768818387313,"version":"3.49.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00280-018-3668-7","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T08:52:49Z","timestamp":1534409569000},"page":"741-755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Liposomal therapies in oncology: does one size fit all?"],"prefix":"10.1007","volume":"82","author":[{"given":"Isabel","family":"Sousa","sequence":"first","affiliation":[]},{"given":"Filipa","family":"Rodrigues","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-6642","authenticated-orcid":false,"given":"Hugo","family":"Prazeres","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5838-9659","authenticated-orcid":false,"given":"Raquel T.","family":"Lima","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9607-6998","authenticated-orcid":false,"given":"Paula","family":"Soares","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"key":"3668_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-med-040210-162544","volume":"63","author":"AZ Wang","year":"2012","unstructured":"Wang AZ, Langer R, Farokhzad OC (2012) Nanoparticle delivery of cancer drugs. Annu Rev Med 63:185\u2013198. https:\/\/doi.org\/10.1146\/annurev-med-040210-162544","journal-title":"Annu Rev Med"},{"issue":"2","key":"3668_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y (2012) Doxil (R)\u2014the first FDA-approved nano-drug: lessons learned. J Control Release 160(2):117\u2013134. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020","journal-title":"J Control Release"},{"issue":"2","key":"3668_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.drudis.2016.11.005","volume":"22","author":"M Cagel","year":"2017","unstructured":"Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA (2017) Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discov Today 22(2):270\u2013281. https:\/\/doi.org\/10.1016\/j.drudis.2016.11.005","journal-title":"Drug Discov Today"},{"issue":"6","key":"3668_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nnano.2017.67","volume":"12","author":"SR D\u2019Mello","year":"2017","unstructured":"D\u2019Mello SR, Cruz CN, Chen ML, Kapoor M, Lee SL, Tyner KM (2017) The evolving landscape of drug products containing nanomaterials in the United States. Nat Nanotechnol 12(6):523\u2013529. https:\/\/doi.org\/10.1038\/nnano.2017.67","journal-title":"Nat Nanotechnol"},{"issue":"6","key":"3668_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/187152006778699121","volume":"6","author":"TM Allen","year":"2006","unstructured":"Allen TM, Cheng WW, Hare JI, Laginha KM (2006) Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem 6(6):513\u2013523","journal-title":"Anticancer Agents Med Chem"},{"issue":"10","key":"3668_CR6","first-page":"2979","volume":"50","author":"WJ Urba","year":"1990","unstructured":"Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith JW, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC et al (1990) Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Cancer Res 50(10):2979\u20132986","journal-title":"Cancer Res"},{"issue":"21","key":"3668_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10(21):1451\u20131458. https:\/\/doi.org\/10.1016\/S1359-6446(05)03575-0","journal-title":"Drug Discov Today"},{"issue":"2","key":"3668_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0005-2736(93)90105-9","volume":"1151","author":"G Haran","year":"1993","unstructured":"Haran G, Cohen R, Bar LK, Barenholz Y (1993) Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151(2):201\u2013215","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"3668_CR9","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","volume":"73","author":"U Prabhakar","year":"2013","unstructured":"Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73(8):2412\u20132417. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4561","journal-title":"Cancer Res"},{"issue":"8","key":"3668_CR10","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.nano.2015.07.015","volume":"11","author":"T Stylianopoulos","year":"2015","unstructured":"Stylianopoulos T, Jain RK (2015) Design considerations for nanotherapeutics in oncology. Nanomedicine 11(8):1893\u20131907. https:\/\/doi.org\/10.1016\/j.nano.2015.07.015","journal-title":"Nanomedicine"},{"issue":"12","key":"3668_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nnano.2007.387","volume":"2","author":"D Peer","year":"2007","unstructured":"Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751\u2013760. https:\/\/doi.org\/10.1038\/nnano.2007.387","journal-title":"Nat Nanotechnol"},{"key":"3668_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jconrel.2017.02.026","volume":"251","author":"K Plourde","year":"2017","unstructured":"Plourde K, Derbali RM, Desrosiers A, Dubath C, Vallee-Belisle A, Leblond J (2017) Aptamer-based liposomes improve specific drug loading and release. J Control Release 251:82\u201391. https:\/\/doi.org\/10.1016\/j.jconrel.2017.02.026","journal-title":"J Control Release"},{"issue":"1","key":"3668_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40169-017-0175-0","volume":"6","author":"S Tran","year":"2017","unstructured":"Tran S, DeGiovanni PJ, Piel B, Rai P (2017) Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med 6(1):44. https:\/\/doi.org\/10.1186\/s40169-017-0175-0","journal-title":"Clin Transl Med"},{"issue":"2","key":"3668_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","volume":"148","author":"F Danhier","year":"2010","unstructured":"Danhier F, Feron O, Preat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148(2):135\u2013146. https:\/\/doi.org\/10.1016\/j.jconrel.2010.08.027","journal-title":"J Control Release"},{"issue":"28","key":"3668_CR15","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1002\/adma.201200454","volume":"24","author":"E Ruoslahti","year":"2012","unstructured":"Ruoslahti E (2012) Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater 24(28):3747\u20133756. https:\/\/doi.org\/10.1002\/adma.201200454","journal-title":"Adv Mater"},{"issue":"9","key":"3668_CR16","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1080\/10717544.2016.1177136","volume":"23","author":"C Zylberberg","year":"2016","unstructured":"Zylberberg C, Matosevic S (2016) Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv 23(9):3319\u20133329. https:\/\/doi.org\/10.1080\/10717544.2016.1177136","journal-title":"Drug Deliv"},{"key":"3668_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"E Perez-Herrero","year":"2015","unstructured":"Perez-Herrero E, Fernandez-Medarde A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52\u201379. https:\/\/doi.org\/10.1016\/j.ejpb.2015.03.018","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"3668_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","volume":"161","author":"T Lammers","year":"2012","unstructured":"Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 161(2):175\u2013187. https:\/\/doi.org\/10.1016\/j.jconrel.2011.09.063","journal-title":"J Control Release"},{"key":"3668_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jconrel.2014.05.002","volume":"190","author":"A Jhaveri","year":"2014","unstructured":"Jhaveri A, Deshpande P, Torchilin V (2014) Stimuli-sensitive nanopreparations for combination cancer therapy. J Control Release 190:352\u2013370. https:\/\/doi.org\/10.1016\/j.jconrel.2014.05.002","journal-title":"J Control Release"},{"key":"3668_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","volume":"200","author":"A Wicki","year":"2015","unstructured":"Wicki A, Witzigmann D, Balasubramanian V, Huwyler J (2015) Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 200:138\u2013157. https:\/\/doi.org\/10.1016\/j.jconrel.2014.12.030","journal-title":"J Control Release"},{"issue":"1","key":"3668_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1021\/nn304474j","volume":"7","author":"KJ Chen","year":"2013","unstructured":"Chen KJ, Liang HF, Chen HL, Wang Y, Cheng PY, Liu HL, Xia Y, Sung HW (2013) A thermoresponsive bubble-generating liposomal system for triggering localized extracellular drug delivery. ACS Nano 7(1):438\u2013446. https:\/\/doi.org\/10.1021\/nn304474j","journal-title":"ACS Nano"},{"key":"3668_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40349-017-0104-0","volume":"5","author":"PC Lyon","year":"2017","unstructured":"Lyon PC, Griffiths LF, Lee J, Chung D, Carlisle R, Wu F, Middleton MR, Gleeson FV, Coussios CC (2017) Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox(R)) using focused ultrasound in patients with liver tumours. J Ther Ultrasound 5:28. https:\/\/doi.org\/10.1186\/s40349-017-0104-0","journal-title":"J Ther Ultrasound"},{"issue":"6","key":"3668_CR23","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1208\/s12248-016-9970-6","volume":"18","author":"HA Havel","year":"2016","unstructured":"Havel HA (2016) Where are the nanodrugs? An industry perspective on development of drug products containing nanomaterials. AAPS J 18(6):1351\u20131353. https:\/\/doi.org\/10.1208\/s12248-016-9970-6","journal-title":"AAPS J"},{"key":"3668_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S (2015) Advances and challenges of liposome assisted drug delivery. Front Pharmacol 6:286. https:\/\/doi.org\/10.3389\/fphar.2015.00286","journal-title":"Front Pharmacol"},{"issue":"3\u20134","key":"3668_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.drudis.2011.09.015","volume":"17","author":"M Slingerland","year":"2012","unstructured":"Slingerland M, Guchelaar HJ, Gelderblom H (2012) Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 17(3\u20134):160\u2013166. https:\/\/doi.org\/10.1016\/j.drudis.2011.09.015","journal-title":"Drug Discov Today"},{"key":"3668_CR26","doi-asserted-by":"publisher","first-page":"e16150477","DOI":"10.1590\/1678-4324-2016150477","volume":"59","author":"H Pandey","year":"2016","unstructured":"Pandey H, Rani R, Agarwal V (2016) Liposome and their applications in cancer therapy. Braz Arch Biol Technol 59:e16150477. https:\/\/doi.org\/10.1590\/1678-4324-2016150477","journal-title":"Braz Arch Biol Technol"},{"key":"3668_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics9020012","author":"U Bulbake","year":"2017","unstructured":"Bulbake U, Doppalapudi S, Kommineni N, Khan W (2017) Liposomal formulations in clinical use: an updated review. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics9020012","journal-title":"Pharmaceutics"},{"issue":"5","key":"3668_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42(5):419\u2013436. https:\/\/doi.org\/10.2165\/00003088-200342050-00002","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3668_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1200\/jco.1998.16.2.683","volume":"16","author":"S Stewart","year":"1998","unstructured":"Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ (1998) Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16(2):683\u2013691. https:\/\/doi.org\/10.1200\/jco.1998.16.2.683","journal-title":"J Clin Oncol"},{"issue":"1","key":"3668_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000178760","volume":"76","author":"S Pignata","year":"2009","unstructured":"Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F (2009) Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Oncology 76(1):49\u201354. https:\/\/doi.org\/10.1159\/000178760","journal-title":"Oncology"},{"issue":"3","key":"3668_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C, Group CBCS (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3):440\u2013449","journal-title":"Ann Oncol"},{"issue":"4","key":"3668_CR32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/cncr.21662","volume":"106","author":"RM Rifkin","year":"2006","unstructured":"Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA (2006) Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer 106(4):848\u2013858. https:\/\/doi.org\/10.1002\/cncr.21662","journal-title":"Cancer"},{"issue":"9","key":"3668_CR33","doi-asserted-by":"publisher","first-page":"e0185654","DOI":"10.1371\/journal.pone.0185654","volume":"12","author":"A Fukuda","year":"2017","unstructured":"Fukuda A, Tahara K, Hane Y, Matsui T, Sasaoka S, Hatahira H, Motooka Y, Hasegawa S, Naganuma M, Abe J, Nakao S, Takeuchi H, Nakamura M (2017) Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. PLoS One 12(9):e0185654. https:\/\/doi.org\/10.1371\/journal.pone.0185654","journal-title":"PLoS One"},{"issue":"1","key":"3668_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bbamem.2004.03.006","volume":"1663","author":"GJ Charrois","year":"2004","unstructured":"Charrois GJ, Allen TM (2004) Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophysica Acta (BBA)-Biomembr 1663(1):167\u2013177","journal-title":"Biochim Biophysica Acta (BBA)-Biomembr"},{"issue":"1","key":"3668_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.10201","volume":"94","author":"L Harris","year":"2002","unstructured":"Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E, Group TDS (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94(1):25\u201336","journal-title":"Cancer"},{"issue":"6","key":"3668_CR36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s002800051025","volume":"45","author":"L Fumagalli","year":"2000","unstructured":"Fumagalli L, Zucchetti M, Parisi I, Vigano MG, Zecca B, Careddu A, D\u2019Incalci M, Lazzarin A (2000) The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi\u2019s sarcoma. Cancer Chemother Pharmacol 45(6):495\u2013501. https:\/\/doi.org\/10.1007\/s002800051025","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"3668_CR37","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","volume":"14","author":"PS Gill","year":"1996","unstructured":"Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME (1996) Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi\u2019s sarcoma. J Clin Oncol 14(8):2353\u20132364. https:\/\/doi.org\/10.1200\/JCO.1996.14.8.2353","journal-title":"J Clin Oncol"},{"issue":"3","key":"3668_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000380913","volume":"89","author":"F Jahn","year":"2015","unstructured":"Jahn F, Jordan K, Behlendorf T, Globig C, Schmoll HJ, Muller-Tidow C, Jordan B (2015) Safety and efficacy of liposomal Cytarabine in the treatment of Neoplastic meningitis. Oncology 89(3):137\u2013142. https:\/\/doi.org\/10.1159\/000380913","journal-title":"Oncology"},{"issue":"3","key":"3668_CR39","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0022-3565(24)29494-5","volume":"298","author":"R Krishna","year":"2001","unstructured":"Krishna R, Webb MS, St Onge G, Mayer LD (2001) Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 298(3):1206\u20131212","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"3668_CR40","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1634\/theoncologist.2015-0391","volume":"21","author":"D Douer","year":"2016","unstructured":"Douer D (2016) Efficacy and safety of vincristine sulfate liposome injection in the treatment of adult acute lymphocytic leukemia. Oncologist 21(7):840\u2013847. https:\/\/doi.org\/10.1634\/theoncologist.2015-0391","journal-title":"Oncologist"},{"key":"3668_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC (2018) CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2017.77.6112","journal-title":"J Clin Oncol"},{"key":"3668_CR42","unstructured":"Stenger M (2017) Liposome-encapsulated daunorubicin and cytarabine for AML subtypes. ASCO POST. http:\/\/www.ascopost.com\/issues\/december-10-2017\/liposome-encapsulated-daunorubicin-and-cytarabine-for-aml-subtypes\/"},{"issue":"10018","key":"3668_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT, Group N-S (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387(10018):545\u2013557. https:\/\/doi.org\/10.1016\/S0140-6736(15)00986-1","journal-title":"Lancet"},{"issue":"7","key":"3668_CR44","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/1756283X17705328","volume":"10","author":"FAU Rahman","year":"2017","unstructured":"Rahman FAU, Ali S, Saif MW (2017) Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. Therap Adv Gastroenterol 10(7):563\u2013572. https:\/\/doi.org\/10.1177\/1756283X17705328","journal-title":"Therap Adv Gastroenterol"},{"issue":"6","key":"3668_CR45","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/bcp.12261","volume":"77","author":"K Venkatakrishnan","year":"2014","unstructured":"Venkatakrishnan K, Liu Y, Noe D, Mertz J, Bargfrede M, Marbury T, Farbakhsh K, Oliva C, Milton A (2014) Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment. Br J Clin Pharmacol 77(6):998\u20131010. https:\/\/doi.org\/10.1111\/bcp.12261","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3668_CR46","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","volume":"26","author":"PA Meyers","year":"2008","unstructured":"Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE, Children\u2019s Oncology G (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival\u2013a report from the Children\u2019s Oncology Group. J Clin Oncol 26(4):633\u2013638. https:\/\/doi.org\/10.1200\/JCO.2008.14.0095","journal-title":"J Clin Oncol"},{"issue":"2","key":"3668_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00000421-199504000-00001","volume":"18","author":"ES Kleinerman","year":"1995","unstructured":"Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N (1995) Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 18(2):93\u201399","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"3668_CR48","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","volume":"16","author":"DW Northfelt","year":"1998","unstructured":"Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16(7):2445\u20132451. https:\/\/doi.org\/10.1200\/JCO.1998.16.7.2445","journal-title":"J Clin Oncol"},{"issue":"14","key":"3668_CR49","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312\u20133322. https:\/\/doi.org\/10.1200\/JCO.2001.19.14.3312","journal-title":"J Clin Oncol"},{"issue":"9","key":"3668_CR50","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1634\/theoncologist.2013-0126","volume":"18","author":"JM Gibson","year":"2013","unstructured":"Gibson JM, Alzghari S, Ahn C, Trantham H, La-Beck NM (2013) The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist 18(9):1022\u20131031. https:\/\/doi.org\/10.1634\/theoncologist.2013-0126","journal-title":"Oncologist"},{"issue":"19","key":"3668_CR51","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","volume":"22","author":"AM Keller","year":"2004","unstructured":"Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C (2004) Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22(19):3893\u20133901. https:\/\/doi.org\/10.1200\/JCO.2004.08.157","journal-title":"J Clin Oncol"},{"issue":"5","key":"3668_CR52","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","volume":"19","author":"G Batist","year":"2001","unstructured":"Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19(5):1444\u20131454. https:\/\/doi.org\/10.1200\/JCO.2001.19.5.1444","journal-title":"J Clin Oncol"},{"key":"3668_CR53","unstructured":"Stenger M (2012) Liposomal vincristine for adult patients with relapsed\/refractory acute lymphoblastic leukemia. The ASCO Post. http:\/\/www.ascopost.com\/issues\/december-15-2012\/liposomal-vincristine-for-adult-patients-withrelapsedrefractory-acute-lymphoblastic-leukemia\/"},{"issue":"5","key":"3668_CR54","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1365-2141.2008.07400.x","volume":"143","author":"R Latagliata","year":"2008","unstructured":"Latagliata R, Breccia M, Fazi P, Iacobelli S, Martinelli G, Di Raimondo F, Sborgia M, Fabbiano F, Pirrotta MT, Zaccaria A, Amadori S, Caramatti C, Falzetti F, Candoni A, Mattei D, Morselli M, Alimena G, Vignetti M, Baccarani M, Mandelli F (2008) Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol 143(5):681\u2013689. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07400.x","journal-title":"Br J Haematol"},{"issue":"10","key":"3668_CR55","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1200\/JCO.1999.17","volume":"17","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D, Cowens W, Howell SB (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17(10):3110\u20133116. https:\/\/doi.org\/10.1200\/JCO.1999.17","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"3668_CR56","doi-asserted-by":"publisher","first-page":"7000","DOI":"10.1200\/JCO.2016.34.15_suppl.7000","volume":"34","author":"JE Lancet","year":"2016","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Chiarella M, Louie AC, Medeiros BC (2016) Final results of a phase III randomized trial of CPX-351 versus 7 + 3 in older patients with newly diagnosed high risk (secondary) AML. J Clin Oncol 34(15_suppl):7000. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.7000","journal-title":"J Clin Oncol"},{"issue":"6","key":"3668_CR57","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cpt.720","volume":"102","author":"BS Adiwijaya","year":"2017","unstructured":"Adiwijaya BS, Kim J, Lang I, Csoszi T, Cubillo A, Chen JS, Wong M, Park JO, Kim JS, Rau KM, Melichar B, Gallego JB, Fitzgerald J, Belanger B, Molnar I, Ma WW (2017) Population Pharmacokinetics of liposomal irinotecan in patients with cancer. Clin Pharmacol Ther 102(6):997\u20131005. https:\/\/doi.org\/10.1002\/cpt.720","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3668_CR58","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1758834016688816","volume":"9","author":"E Kipps","year":"2017","unstructured":"Kipps E, Young K, Starling N (2017) Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Ther Adv Med Oncol 9(3):159\u2013170. https:\/\/doi.org\/10.1177\/1758834016688816","journal-title":"Ther Adv Med Oncol"},{"key":"3668_CR59","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/TCRM.S5688","volume":"6","author":"L Kager","year":"2010","unstructured":"Kager L, Potschger U, Bielack S (2010) Review of mifamurtide in the treatment of patients with osteosarcoma. Ther Clin Risk Manag 6:279\u2013286","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"3668_CR60","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","volume":"119","author":"X Wang","year":"2007","unstructured":"Wang X, Ishida T, Kiwada H (2007) Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 119(2):236\u2013244. https:\/\/doi.org\/10.1016\/j.jconrel.2007.02.010","journal-title":"J Control Release"},{"issue":"8","key":"3668_CR61","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","volume":"14","author":"PS Gill","year":"1996","unstructured":"Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G (1996) Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi\u2019s sarcoma. J Clin Oncol 14(8):2353\u20132364","journal-title":"J Clin Oncol"},{"issue":"1","key":"3668_CR62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/2040620713519016","volume":"5","author":"P Pathak","year":"2014","unstructured":"Pathak P, Hess R, Weiss MA (2014) Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: a review of literature. Ther Adv Hematol 5(1):18\u201324. https:\/\/doi.org\/10.1177\/2040620713519016","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"3668_CR63","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/bjc.2011.593","volume":"106","author":"J Alexandre","year":"2012","unstructured":"Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Maenpaa J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E (2012) CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. Br J Cancer 106(4):633\u2013637. https:\/\/doi.org\/10.1038\/bjc.2011.593","journal-title":"Br J Cancer"},{"issue":"1","key":"3668_CR64","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/IGC.0b013e3181c16ba1","volume":"20","author":"A Oaknin","year":"2010","unstructured":"Oaknin A, Barretina P, Perez X, Jimenez L, Velasco M, Alsina M, Brunet J, Germa JR, Beltran M (2010) CA-125 response patterns in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD). Int J Gynecol Cancer 20(1):87\u201391. https:\/\/doi.org\/10.1111\/IGC.0b013e3181c16ba1","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"3668_CR65","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ygyno.2009.04.037","volume":"114","author":"P Power","year":"2009","unstructured":"Power P, Stuart G, Oza A, Provencher D, Bentley JR, Miller WH, Pouliot JF (2009) Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol 114(3):410\u2013414. https:\/\/doi.org\/10.1016\/j.ygyno.2009.04.037","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3668_CR66","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1634\/theoncologist.12-1-72","volume":"12","author":"RL Coleman","year":"2007","unstructured":"Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ (2007) Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist 12(1):72\u201378. https:\/\/doi.org\/10.1634\/theoncologist.12-1-72","journal-title":"Oncologist"},{"issue":"1","key":"3668_CR67","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ygyno.2006.02.026","volume":"103","author":"G Gossner","year":"2006","unstructured":"Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ (2006) CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol 103(1):212\u2013218. https:\/\/doi.org\/10.1016\/j.ygyno.2006.02.026","journal-title":"Gynecol Oncol"},{"issue":"3","key":"3668_CR68","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/IGC.0b013e3181a1c7aa","volume":"19","author":"JS Tanguay","year":"2009","unstructured":"Tanguay JS, Ansari J, Buckley L, Fernando I (2009) Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment. Int J Gynecol Cancer 19(3):361\u2013366. https:\/\/doi.org\/10.1111\/IGC.0b013e3181a1c7aa","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"3668_CR69","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ygyno.2008.01.039","volume":"109","author":"G Ferrandina","year":"2008","unstructured":"Ferrandina G, Ludovisi M, Corrado G, Carone V, Petrillo M, Scambia G (2008) Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 109(2):187\u2013193. https:\/\/doi.org\/10.1016\/j.ygyno.2008.01.039","journal-title":"Gynecol Oncol"},{"issue":"17","key":"3668_CR70","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/jnci\/djr282","volume":"103","author":"CK Lee","year":"2011","unstructured":"Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ (2011) Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst 103(17):1338\u20131342. https:\/\/doi.org\/10.1093\/jnci\/djr282","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"3668_CR71","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/annonc\/mdi078","volume":"16","author":"A Fabi","year":"2005","unstructured":"Fabi A, Ferretti G, Salesi N, Papaldo P, Carlini P, Ciccarese M, Di Cocco B, Cecere F, Nardoni C, Felici A, Cognetti F (2005) Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients? Ann Oncol 16(3):516\u2013517. https:\/\/doi.org\/10.1093\/annonc\/mdi078","journal-title":"Ann Oncol"},{"issue":"12","key":"3668_CR72","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/jnci\/92.12.987","volume":"92","author":"MS Orr","year":"2000","unstructured":"Orr MS, O\u2019Connor PM, Kohn KW (2000) Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells. J Natl Cancer Inst 92(12):987\u2013994","journal-title":"J Natl Cancer Inst"},{"issue":"28","key":"3668_CR73","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1200\/JCO.2008.21.4791","volume":"27","author":"L Gianni","year":"2009","unstructured":"Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN (2009) Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 27(28):4798\u20134808. https:\/\/doi.org\/10.1200\/JCO.2008.21.4791","journal-title":"J Clin Oncol"},{"issue":"2","key":"3668_CR74","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-006-9492-5","volume":"106","author":"E Arriola","year":"2007","unstructured":"Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2007) Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106(2):181\u2013189. https:\/\/doi.org\/10.1007\/s10549-006-9492-5","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"3668_CR75","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3816\/CBC.2010.n.064","volume":"10","author":"R Torrisi","year":"2010","unstructured":"Torrisi R, Cardillo A, Cancello G, Dellapasqua S, Balduzzi A, Ghisini R, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M (2010) Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. Clin Breast Cancer 10(6):483\u2013488. https:\/\/doi.org\/10.3816\/CBC.2010.n.064","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"3668_CR76","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3816\/CLM.2008.n.041","volume":"8","author":"M Offidani","year":"2008","unstructured":"Offidani M, Corvatta L, Polloni C, Piersantelli MN, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P (2008) Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide\/ anthracycline-based therapy. Clin Lymphoma Myeloma 8(5):294\u2013299. https:\/\/doi.org\/10.3816\/CLM.2008.n.041","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"3668_CR77","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2013.11.015","volume":"345","author":"K Yokoi","year":"2014","unstructured":"Yokoi K, Tanei T, Godin B, van de Ven AL, Hanibuchi M, Matsunoki A, Alexander J, Ferrari M (2014) Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. Cancer Lett 345(1):48\u201355. https:\/\/doi.org\/10.1016\/j.canlet.2013.11.015","journal-title":"Cancer Lett"},{"issue":"3","key":"3668_CR78","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ygyno.2015.06.025","volume":"138","author":"J Erriquez","year":"2015","unstructured":"Erriquez J, Becco P, Olivero M, Ponzone R, Maggiorotto F, Ferrero A, Scalzo MS, Canuto EM, Sapino A, Verdun di Cantogno L, Bruna P, Aglietta M, Di Renzo MF, Valabrega G (2015) TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. Gynecol Oncol 138(3):627\u2013633. https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.025","journal-title":"Gynecol Oncol"},{"issue":"3","key":"3668_CR79","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0002-9440(10)64952-8","volume":"156","author":"TA Jarvinen","year":"2000","unstructured":"Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J (2000) Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156(3):839\u2013847","journal-title":"Am J Pathol"},{"issue":"3","key":"3668_CR80","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10549-011-1694-9","volume":"129","author":"Y Du","year":"2011","unstructured":"Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z, Shao Z, Lu J (2011) The role of topoisomerase IIalpha in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures. Breast Cancer Res Treat 129(3):839\u2013848. https:\/\/doi.org\/10.1007\/s10549-011-1694-9","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"3668_CR81","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2005.02.9264","volume":"24","author":"T Scandinavian Breast Group","year":"2006","unstructured":"Scandinavian Breast Group T, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Nilsson J, Bergh J (2006) Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2\/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24(16):2428\u20132436. https:\/\/doi.org\/10.1200\/JCO.2005.02.9264","journal-title":"J Clin Oncol"},{"issue":"10","key":"3668_CR82","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1535-7163.1207.3.10","volume":"3","author":"V Durbecq","year":"2004","unstructured":"Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D (2004) Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 3(10):1207\u20131214","journal-title":"Mol Cancer Ther"},{"key":"3668_CR83","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev.pharmtox.41.1.53","volume":"41","author":"TK Li","year":"2001","unstructured":"Li TK, Liu LF (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 41:53\u201377. https:\/\/doi.org\/10.1146\/annurev.pharmtox.41.1.53","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"3668_CR84","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.canlet.2011.07.017","volume":"313","author":"H Green","year":"2011","unstructured":"Green H, Stal O, Bachmeier K, Backlund LM, Carlsson L, Hansen J, Lagerlund M, Norberg B, Franzen A, Aleskog A, Malmstrom A (2011) Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified. Cancer Lett 313(2):145\u2013153. https:\/\/doi.org\/10.1016\/j.canlet.2011.07.017","journal-title":"Cancer Lett"},{"issue":"45","key":"3668_CR85","doi-asserted-by":"publisher","first-page":"72654","DOI":"10.18632\/oncotarget.12056","volume":"7","author":"F Perrone","year":"2016","unstructured":"Perrone F, Baldassarre G, Indraccolo S, Signoriello S, Chiappetta G, Esposito F, Ferrandina G, Franco R, Mezzanzanica D, Sonego M, Zulato E, Zannoni GF, Canzonieri V, Scambia G, Sorio R, Savarese A, Breda E, Scollo P, Ferro A, Tamberi S, Febbraro A, Natale D, Di Maio M, Califano D, Scognamiglio G, Lorusso D, Canevari S, Losito S, Gallo C, Pignata S (2016) Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. Oncotarget 7(45):72654\u201372661. https:\/\/doi.org\/10.18632\/oncotarget.12056","journal-title":"Oncotarget"},{"issue":"1","key":"3668_CR86","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/0008-5472.CAN-13-2620","volume":"74","author":"DH Shin","year":"2014","unstructured":"Shin DH, Choi YJ, Park JW (2014) SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin. Cancer Res 74(1):298\u2013308. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2620","journal-title":"Cancer Res"},{"issue":"11","key":"3668_CR87","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/onc.2010.512","volume":"30","author":"H Prazeres","year":"2011","unstructured":"Prazeres H, Torres J, Rodrigues F, Pinto M, Pastoriza MC, Gomes D, Cameselle-Teijeiro J, Vidal A, Martins TC, Sobrinho-Simoes M, Soares P (2011) Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene 30(11):1302\u20131317. https:\/\/doi.org\/10.1038\/onc.2010.512","journal-title":"Oncogene"},{"issue":"9","key":"3668_CR88","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.addr.2003.12.003","volume":"56","author":"NS Chung","year":"2004","unstructured":"Chung NS, Wasan KM (2004) Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev 56(9):1315\u20131334. https:\/\/doi.org\/10.1016\/j.addr.2003.12.003","journal-title":"Adv Drug Deliv Rev"},{"issue":"16","key":"3668_CR89","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1158\/0008-5472.CAN-12-0203","volume":"72","author":"PA Cowin","year":"2012","unstructured":"Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, Etemadmoghadam D, Ftouni S, Galletta L, Anglesio MS, Hendley J, Bowes L, Sheppard KE, Christie EL, Pearson RB, Harnett PR, Heinzelmann-Schwarz V, Friedlander M, McNally O, Quinn M, Campbell P, deFazio A, Bowtell DD (2012) LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Aust Ovarian Cancer Res 72(16):4060\u20134073. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0203","journal-title":"Aust Ovarian Cancer Res"},{"issue":"2","key":"3668_CR90","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ijc.28500","volume":"135","author":"V Lopes-Rodrigues","year":"2014","unstructured":"Lopes-Rodrigues V, Seca H, Sousa D, Sousa E, Lima RT, Vasconcelos MH (2014) The network of P-glycoprotein and microRNAs interactions. Int J Cancer 135(2):253\u2013263. https:\/\/doi.org\/10.1002\/ijc.28500","journal-title":"Int J Cancer"},{"issue":"8","key":"3668_CR91","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2174\/1389200216666150223152958","volume":"15","author":"Y Liu","year":"2014","unstructured":"Liu Y, Rohrs J, Wang P (2014) Advances and challenges in the use of nanoparticles to optimize PK\/PD interactions of combined anti-cancer therapies. Curr Drug Metab 15(8):818\u2013828","journal-title":"Curr Drug Metab"},{"issue":"1","key":"3668_CR92","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00280-014-2477-x","volume":"74","author":"O Arrieta","year":"2014","unstructured":"Arrieta O, Medina LA, Estrada-Lobato E, Ramirez-Tirado LA, Mendoza-Garcia VO, de la Garza-Salazar J (2014) High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99 m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin. Cancer Chemother Pharmacol 74(1):211\u2013215. https:\/\/doi.org\/10.1007\/s00280-014-2477-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"3668_CR93","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/jog.13334","volume":"43","author":"Y Yamada","year":"2017","unstructured":"Yamada Y, Kawaguchi R, Ito F, Iwai K, Niiro E, Shigetomi H, Tanase Y, Kobayashi H (2017) Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer. J Obstet Gynaecol Res 43(7):1194\u20131199. https:\/\/doi.org\/10.1111\/jog.13334","journal-title":"J Obstet Gynaecol Res"},{"issue":"7","key":"3668_CR94","doi-asserted-by":"publisher","first-page":"472","DOI":"10.4161\/cbt.19593","volume":"13","author":"T Franchina","year":"2012","unstructured":"Franchina T, Adamo B, Ricciardi GR, Caristi N, Agostino RM, Proto C, Adamo V (2012) Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports. Cancer Boil Therapy 13(7):472\u2013476. https:\/\/doi.org\/10.4161\/cbt.19593","journal-title":"Cancer Boil Therapy"},{"issue":"2","key":"3668_CR95","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s11096-016-0278-5","volume":"38","author":"M Uriarte-Pinto","year":"2016","unstructured":"Uriarte-Pinto M, Escolano-Pueyo A, Gimeno-Ballester V, Pascual-Martinez O, Abad-Sazatornil MR, Agustin-Ferrandez MJ (2016) Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer. Int J Clin Pharm 38(2):446\u2013453. https:\/\/doi.org\/10.1007\/s11096-016-0278-5","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"3668_CR96","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-14-1882","volume":"21","author":"MH Kang","year":"2014","unstructured":"Kang MH et al (2014) Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res 21(5):1139\u20131150. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1882","journal-title":"Clin Cancer Res"},{"issue":"7391","key":"3668_CR97","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"Jordi Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Leh\u00e1r J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jan\u00e9-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603. https:\/\/doi.org\/10.1038\/nature11003\/. https:\/\/www.nature.com\/articles\/nature11003#supplementary-information","journal-title":"Nature"},{"issue":"2","key":"3668_CR98","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ajps.2013.07.010","volume":"8","author":"YZ Fan","year":"2013","unstructured":"Fan YZ (2013) Development of liposomal formulations: from concept to clinical investigations. Asian J Pharm Sci 8(2):81\u201387. https:\/\/doi.org\/10.1016\/j.ajps.2013.07.010","journal-title":"Asian J Pharm Sci"},{"issue":"1","key":"3668_CR99","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tibtech.2013.09.007","volume":"32","author":"GT Noble","year":"2014","unstructured":"Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B (2014) Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol 32(1):32\u201345. https:\/\/doi.org\/10.1016\/j.tibtech.2013.09.007","journal-title":"Trends Biotechnol"},{"key":"3668_CR100","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2018.02.015","volume":"275","author":"M Merino","year":"2018","unstructured":"Merino M, Zalba S, Garrido MJ (2018) Immunoliposomes in clinical oncology: State of the art and future perspectives. J Control Release 275:162\u2013176. https:\/\/doi.org\/10.1016\/j.jconrel.2018.02.015","journal-title":"J Control Release"},{"issue":"8","key":"3668_CR101","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1470-2045(18)30332-2","volume":"19","author":"PC Lyon","year":"2018","unstructured":"Lyon PC, Gray MD, Mannaris C, Folkes LK, Stratford M, Campo L, Chung DY, Scott S, Anderson M, Goldin R (2018) Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. Lancet Oncol 19(8):1027\u20131039","journal-title":"Lancet Oncol"},{"issue":"8","key":"3668_CR102","first-page":"1027","volume":"19","author":"WY Tak","year":"2017","unstructured":"Tak WY, Lin S-M, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng C-Y (2017) Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions. Clin Cancer Res 19(8):1027\u20131039","journal-title":"Clin Cancer Res"},{"key":"3668_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23020288","author":"N Lamichhane","year":"2018","unstructured":"Lamichhane N, Udayakumar TS, D\u2019Souza WD, Simone CB, Raghavan SR, Polf J, Mahmood J (2018) Liposomes: clinical applications and potential for image-guided drug delivery. Molecules. https:\/\/doi.org\/10.3390\/molecules23020288","journal-title":"Molecules"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-018-3668-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3668-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3668-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T10:46:42Z","timestamp":1751798802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-018-3668-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":103,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3668"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3668-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]},"assertion":[{"value":"23 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}